Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

计划入组 55 人 · 首次发布于 2013 年 9 月 27 日

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

计划入组 42 人 · 首次发布于 2020 年 4 月 2 日

Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors

计划入组 74 人 · 首次发布于 2010 年 6 月 7 日

focal adhesion kinase

FAK inhibitors (glioblastoma)

FAK inhibitor (Zeling Biomedical)

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

InxMed's Ifebemtinib Receives Breakthrough Therapy Designation for NSCLC with KRAS G12C Mutation

Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC

Verastem Oncology Seeks FDA Approval for Avutometinib and Defactinib Combination in Low-Grade Serous Ovarian Cancer